Regional distribution of benzodiazepine binding sites in the human newborn and infant hypothalamus. A quantitative autoradiographic study.
Using in vitro quantitative autoradiography and [3H]flunitrazepam we examined the rostrocaudal distribution of benzodiazepine binding sites in the human neonate/infant hypothalamus. The autoradiographic analysis shows the presence of a heterogeneous distribution throughout the rostrocaudal extent of this brain structure. High [3H]flunitrazepam binding corresponds primarily to the diagonal band of Broca and the preoptic region. The labelling in the preoptic region showed a rostrocaudal increase, contrasting in that with the other hypothalamic structures. Intermediate densities were present in the septohypothalamic, suprachiasmatic, periventricular and paraventricular nuclei as well as in the mammillary complex. Low binding was observed in the other hypothalamic structures. The benzodiazepine binding sites analyzed belong mostly to type II receptors. In an attempt to unravel possible differences related to age, we compared the autoradiographic distribution in three postnatal age ranges. The topographical distribution of these binding sites was almost identical in each period analyzed. We found, however, that benzodiazepine binding is generally low in the neonatal period and a tendency in increasing densities is observed during development. Taken together, these results provide evidence for a large distribution of benzodiazepine binding sites in neonate/infant hypothalamus, suggesting their implication in the development of this brain structure and the maintenance of its various functions.
Najimi
M
M
Unité Génie Biologique, Departmente de Biologie & Biotechnologie, F.S.T. de Beni-Mellal, B.P: 523, 2300 Beni-Mellal, Morocco. mnajimi1@fstbm.ac.ma
Bennis
M
M
Moyse
E
E
Miachon
S
S
Kopp
N
N
Chigr
F
F
D000367:Age Factors; D007025:Anterior Hypothalamic Nucleus / Q000166:cytology / Q000254:growth & development / Q000378:metabolism; D014151:Anti-Anxiety Agents / Q000494:pharmacology; D001665:Binding Sites / Q000187:drug effects / Q000502:physiology; D005260:Female; D005445:Flunitrazepam / Q000493:pharmacokinetics; D006801:Humans; D007031:Hypothalamus / Q000166:cytology / Q000254:growth & development* / Q000378:metabolism*; D007033:Hypothalamus, Middle / Q000166:cytology / Q000254:growth & development / Q000378:metabolism; D007034:Hypothalamus, Posterior / Q000166:cytology / Q000254:growth & development / Q000378:metabolism; D007223:Infant; D007231:Infant, Newborn; D008297:Male; D009474:Neurons / Q000166:cytology / Q000378:metabolism*; D011869:Radioligand Assay; D011963:Receptors, GABA-A / Q000378:metabolism*; D014316:Tritium / Q000493:pharmacokinetics; D005680:gamma-Aminobutyric Acid / Q000378:metabolism
D014151:Anti-Anxiety Agents; D011963:Receptors, GABA-A; D014316:Tritium; D005680:gamma-Aminobutyric Acid; D005445:Flunitrazepam